Jordan Harbinger avatar

Dexa/Jordan Harbinger

Learn more
Published Jun 18, 2024

1005: David Fajgenbaum | Leveraging AI to Cure Rare Diseases

Dive into the groundbreaking work of physician David Fajgenbaum as he leverages AI and innovation to repurpose existing drugs for rare diseases, sharing his personal battle with Castleman disease and the potential for transformative AI technologies in medicine.
Episode Highlights
The Jordan Harbinger Show logo

Topics covered

Popular Clips

Questions from this episode

Episode Highlights

  • Systemic Barriers

    highlights the economic and systemic barriers to repurposing existing drugs for rare diseases. He explains that pharmaceutical companies lack incentives to find new uses for old drugs due to the high costs of clinical trials and low profitability of generic drugs 1. This systemic issue leaves many potential treatments undiscovered, as illustrated by David's own experience with Castleman disease, where outdated databases and lack of awareness hindered timely treatment 2.

    The system we have does a really good job of incentivizing pharma to create new drugs, but it also makes it so that these drug companies are not incentivized at all to find new uses for medicines.

    ---

       

    Research Gaps

    David discusses the lack of collaboration in disease research, which hampers the development of treatments for rare diseases. He initially believed in a coordinated effort to tackle these diseases but found the reality to be chaotic and uncoordinated 3. Despite this, he found hope in the simplicity of many rare diseases, which are often less complex than more studied conditions, suggesting that applying existing technologies could yield significant breakthroughs 4.

    The more I understood rare diseases, the more I realized it wasn't that they were particularly complicated, just no one was putting any effort into figuring them out.

    ---

       

    Nonprofit Solutions

    David's nonprofit, Every Cure, aims to repurpose existing drugs for rare diseases, addressing the lack of financial incentives for pharmaceutical companies. He emphasizes that 80% of FDA-approved drugs are generic and under-researched for new uses 5. Every Cure is building a platform to share information and gather data from patients who have benefited from off-label drug use, aiming to accelerate the discovery of new treatments 6.

    We believe that every drug should be utilized for every disease it possibly can, regardless of whether it's profitable or not.

    ---

Related Episodes